Eltrombopag Ethyl Ester Impurity
Parent: Eltrombopag
Eltrombopag Impurity 28 (Trifluoroacetate)
Parent: Eltrombopag
Eltrombopag Impurity 41 (Trifluoroacetate)
Parent: Eltrombopag
Eltrombopag Impurity 9 (Trifluoroacetate)
Parent: Eltrombopag
Eltrombopag Olamine Reference Standard
Parent: Eltrombopag / Eltrombopag Olamine
Eltrombopag Pyrazole Impurity
Parent: Eltrombopag
Eltrombopag Reference Standard
Parent: Eltrombopag
N-Nitroso Eltrombopag Amino Impurity
Parent: Eltrombopag
N-Nitroso Eltrombopag Methyl Ester Impurity
Parent: Eltrombopag
![2-aminoethyl (E)-3'-(2-(1-(3,4-dimethylphenyl)-3-methyl-5-oxo-1,5-dihydro-4H-pyrazol-4-ylidene)hydrazineyl)-2'-hydroxy-[1,1'-biphenyl]-3-carboxylate](https://veeprho.com/wp-content/uploads/2025/11/2-aminoethyl-E-3-2-1-34-dimethylphenyl-3-methyl-5-oxo-15-dihydro-4H-pyrazol-4-ylidenehydrazineyl-2-hydroxy-11-biphenyl-3-carboxylate-NA-VE0025853.png "2-aminoethyl (E)-3'-(2-(1-(3,4-dimethylphenyl)-3-methyl-5-oxo-1,5-dihydro-4H-pyrazol-4-ylidene)hydrazineyl)-2'-hydroxy-[1,1'-biphenyl]-3-carboxylate")
2-aminoethyl (E)-3'-(2-(1-(3,4-dimethylphenyl)-3-methyl-5-oxo-1,5-dihydro-4H-pyrazol-4-ylidene)hydrazineyl)-2'-hydroxy-[1,1'-biphenyl]-3-carboxylate
Parent: Eltrombopag
![2'-hydroxy-3'-nitro-[1,1'-biphenyl]-3-carboxylic acid](https://veeprho.com/wp-content/uploads/2026/04/2-hydroxy-3-nitro-11-biphenyl-3-carboxylic-acid-376591-95-6-VE0024674-2486.png "2'-hydroxy-3'-nitro-[1,1'-biphenyl]-3-carboxylic acid")
2'-hydroxy-3'-nitro-[1,1'-biphenyl]-3-carboxylic acid
Parent: Eltrombopag
![2'-methoxy-3'-nitro-[1,1'-biphenyl]-3-carboxylic acid](https://veeprho.com/wp-content/uploads/2026/04/2-methoxy-3-nitro-11-biphenyl-3-carboxylic-acid-376591-94-5-VE0024675-f8b9.png "2'-methoxy-3'-nitro-[1,1'-biphenyl]-3-carboxylic acid")
2'-methoxy-3'-nitro-[1,1'-biphenyl]-3-carboxylic acid
Parent: Eltrombopag
Eltrombopag Related Compound
Impurities in eltrombopag can develop during manufacturing, handling, or storage. Monitoring and controlling these impurities is critical to ensure the medication’s safety, efficacy, and quality.
Types of Impurities in Eltrombopag
Related Substances
These are byproducts or chemically related compounds formed during the synthesis of eltrombopag. Strict monitoring ensures the drug’s purity and effectiveness.
Degradation Products
Eltrombopag may degrade when exposed to improper storage conditions, such as heat, light, or moisture. Proper storage in a cool, dry place is essential to maintain its stability.
Residual Solvents
Trace amounts of solvents used during manufacturing may remain in the final product. Regulatory guidelines ensure these are within acceptable limits to minimize risks to patients.
Analytical Techniques for Monitoring Impurities
Advanced techniques such as High-Performance Liquid Chromatography (HPLC) and Mass Spectrometry (LC-MS) are used to detect and quantify impurities, ensuring eltrombopag complies with stringent quality standards.
FAQ
Patients taking eltrombopag should monitor their platelet count regularly to avoid the risk of blood clots. Liver function tests should also be performed periodically, as the medication may cause liver abnormalities. Avoid taking eltrombopag with dairy products, calcium-fortified juices, or mineral supplements, as these can interfere with absorption.
Avoid consuming foods high in calcium, such as dairy products and calcium-fortified juices, as they can reduce the absorption of eltrombopag. These foods should not be consumed within four hours before or after taking the medication.
The duration of eltrombopag treatment depends on the condition being treated and the patient’s response to the medication. It is typically taken daily as prescribed by a healthcare provider, with adjustments based on platelet count and liver function.
Eltrombopag should be taken on an empty stomach, at least one hour before or two hours after a meal. Avoid taking it with foods containing calcium, as these can interfere with the drug’s absorption.